Serialization got you to the starting line. DSCSA compliance in 2026 is a different race: item-level traceability data must move between every trading partner through interoperable, standardized exchanges, at scale, under exception and with evidence you can produce on demand.
This guide translates those obligations into an operations-first checklist: what each requirement demands, who owns it (Reg/QA, Packaging Ops, Supply Chain, IT), and what auditors and regulators will expect to see. It also walks through the failure modes that quietly sink programs in practice, including partner data mismatches, EPCIS gaps, and exceptions with no defined response path.
Inside you’ll find a breakdown of requirement categories, a trackable roadmap with assigned owners, a requirement-to-evidence mapping table, a printable 2026 checklist and a glossary with FAQs so cross-functional teams stop talking past each other.
TABLE OF CONTENTS
DSCSA Compliance Requirements: A Practical Checklist for 2026
Key takeaways: What you must have in place for DSCSA compliance in 2026
What DSCSA compliance means in 2026
What “compliant” looks like on the ground
Who must comply with DSCSA and where responsibility sits
DSCSA compliance requirements (grouped by requirement type)
Evidence and audit expectations
What auditors typically ask for
Building a DSCSA readiness attestation
Step-by-step DSCSA compliance implementation roadmap
Common failure modes (and how to prevent them)
Inconsistent suspect product handling
Partner onboarding takes months
Teams optimize serialization but ignore interoperability
Printable DSCSA compliance checklist for 2026
Must-have (minimum viable compliance)
Mature program (resilience and efficiency)
What are the DSCSA compliance requirements in 2026?
What does DSCSA interoperability mean in practice?
What’s the difference between DSCSA serialization and interoperability?
What DSCSA records do we need to keep and for how long?
How fast do we need to produce DSCSA evidence during an investigation or recall?
What triggers DSCSA product verification requirements?
What is a suspect product vs. an illegitimate product?
What is an authorized trading partner and how do we verify it?
Do small dispensers have different DSCSA requirements in 2026?
What are the most common DSCSA data exchange failures?
Do we need EPCIS for DSCSA compliance?
How should we prepare for DSCSA audits without over-lawyering the program?
What’s the role of the FDA DSCSA portal?
DSCSA compliance has a specific operational definition now. Your organization must identify products at the package level, exchange required tracing data electronically with trading partners and execute verification and investigation workflows with documented evidence you can produce on demand.
Serialization gave you a foundation. DSCSA in 2026 builds an entire house on top of it.
The law requires an interoperable, electronic system for identifying and tracing prescription drugs at the package level, plus verification capabilities and rapid response protocols when something looks wrong.
Having serial numbers on your packages is the bare minimum. You need functioning data exchange with your trading partners, exception handling that holds up under pressure and retrieval processes that produce six years of records on short notice.
Most exemptions already expired in 2025. Even though a few exemptions still exist (small dispenser exemptions run until November 27, 2026), don’t build your strategy around them.
DSCSA compliance touches four groups, and none of them can carry it alone.
If any one of these teams thinks DSCSA is “someone else’s problem,” you have a gap that will show up at the worst possible time.
The content in this guide is for informational purposes only and does not constitute legal advice. Consult qualified legal counsel for compliance decisions specific to your organization.
DSCSA compliance obligations follow the product, and they attach to your role in the supply chain. If you manufacture, repackage, distribute or dispense covered prescription drugs, you have specific requirements tied to that function. Third-party logistics providers carry licensure and reporting obligations that support the broader ecosystem.
The FDA defines “trading partners” by what they do with the product. Your obligations map to your role: manufacturer, repackager, wholesale distributor or dispenser. If your organization fills multiple roles (and plenty do), you comply with each set of applicable requirements. They don’t stack or duplicate, but you can’t pick the lightest version and call it a day.
Responsibility rarely lives in one department. Reg/QA, Packaging Ops, Supply Chain and IT each own a piece. The table below breaks down what each trading partner role is responsible for and what evidence you should have ready.
| Trading partner role | Typical responsibilities | Typical evidence |
| Manufacturer | Assign and maintain product identifiers; provide tracing data; respond to verification requests | PI/master data, EPCIS outputs, verification response logs, SOPs |
| Repackager | Handle new packaging/labeling events; maintain linkage to original product identifiers | Transformation/aggregation records, EPCIS event sets, SOPs |
| Wholesale distributor | Receive and pass tracing data; verify saleable returns; handle exceptions | Partner connectivity tests, returns verification logs, investigation records |
| Dispenser | Receive and maintain tracing data; run suspect/illegitimate product workflows; respond to requests | Receiving procedures, quarantine logs, request-response drills |
| 3PL | Maintain licensure/reporting visibility; support secure handling | Facility licensure records, annual reporting confirmation, SOPs |
At Systech, we frame 2026 DSCSA readiness around four pillars: EPCIS or TI/TS, verification, credentialing and tracing. Each pillar carries its own owners, evidence, and failure modes, and weakness in any single one unravels the others. Serialization sits underneath all four as the foundation (no serialized data, nothing to exchange, verify, or trace), and six-year recordkeeping is the cross-cutting retention obligation every pillar feeds into.
In practice, this means:
Quick clarifier: serialization creates product identifier events. EPCIS / TI/TS exchanges those events across companies. One without the other leaves you half-built.
Evidence to have ready: partner mapping specs, test scripts and results, monitoring dashboards, error taxonomies, SLA reports, line qualification docs, batch records, commissioning and aggregation reports.
In practice, this means:
Evidence to have ready: verification SOPs, transaction logs, response SLAs, exception-handling outcomes.
In practice, this means:
Evidence to have ready: onboarding checklist, partner master list, credential validation records, connectivity test evidence.
In practice, this means:
Evidence to have ready: quarantine logs, investigation records, notification records, CAPAs, training records, retention policy, access control matrix, retrieval runbooks, sample exports, retrieval drill results.
Having the right capabilities means nothing if you can’t prove them the second someone asks. Audit readiness comes down to producing the right evidence, fast, across serialization, data exchange, verification, investigations and record retention.
Auditors and inspectors tend to pull from the same playbook. They want to see:
Consider assembling an internal readiness packet that documents your program scope, controls, evidence index and the date of your last retrieval drill. Frame it around demonstrated capabilities and proof artifacts rather than legal conclusions. Your goal is to show what your program does and how you can prove it, not to make claims your legal team hasn’t reviewed.
Audit expectations vary by regulator, customer and specific circumstances. Use this as a documentation planning framework, not legal guidance.
The table below maps each evidence type to an owner, a system of record and a realistic plan for producing it within 24 to 48 hours. If any row makes your team nervous, that’s where your next drill should focus.
| Evidence type | Primary owner | How to produce in 24-48 hours |
| Partner connectivity and exchange success | IT/ Traceability lead | Export 30 to 90 days of message logs, success rates and sample transactions |
| PI/serialization proof | Packaging Ops | Pull batch/lot commissioning, aggregation and rework reports |
| Verification proof | Supply Chain/QA | Export verification requests/responses and SLA compliance data |
| Suspect/illegitimate investigations | QA/ Regulatory | Produce case file with timeline, evidence and notifications |
| Retention proof | IT/QA | Provide retention policy, access audit log and sample retrieval drill output |
You don’t need to build all of this from scratch. A solid DSCSA program moves through a clear sequence, and the right platform handles most of the technical lift so your team can focus on decisions, not wiring.
Most DSCSA failures don’t come from lack of effort. They come from partner connectivity gaps, data quality drift, and exception handling under time pressure. The good news: you don’t have to solve these alone. Systech’s Exception Manager, UniTrace®, and UniSeries® solutions were built for exactly these failure points, with 85% of the top 20 pharma companies trusting us to protect their products and reputations.
Finally, the checklist below tells you what to have in place. If you can check every “must-have” item, you’re functionally compliant. The “mature program” items reduce disruption risk, cut exception volume and make audits significantly less painful.
Program and scope
Product identification
Interoperable data exchange
Verification systems
Recordkeeping and response
Trading partner controls
You need to identify products at the package level, exchange tracing data electronically with trading partners, run verification and investigation workflows, retain records for six years and transact only with authorized trading partners. The full requirements vary by your role (manufacturer, repackager, wholesale distributor, dispenser or 3PL).
You can exchange required transaction data electronically with your direct trading partners, securely and consistently, without manual re-entry. That means validated connections, standardized formats and error handling that works under real conditions.
Serialization creates product identifier events at the package level. Interoperability moves traceability data between companies. You need both. A perfectly serialized product that can’t be traced across your supply chain still leaves you noncompliant.
You must retain transaction information, transaction history and transaction statements for at least six years. The harder part is retrieval. Plan to produce records within 24 to 48 hours of a request.
The law requires responses within statutory timeframes. Operationally, plan for 24 to 48 hours. Build a retrieval runbook, assign owners and drill it quarterly so your team can hit that window across time zones.
Suspect or illegitimate product investigations trigger verification obligations. Saleable returns scenarios also require verification where applicable. Your systems need documented workflows for both.
A suspect product raises questions about legitimacy based on specific criteria (counterfeit, diverted, stolen, intentionally adulterated or appearing unfit). An illegitimate product is one you’ve confirmed falls into one of those categories after investigation. The distinction matters because an illegitimate product triggers FDA notification and disposition requirements.
An authorized trading partner holds valid licensure or registration for their role in the supply chain. Verify ATP status through state licensure databases and FDA registration records. Build these checks into your onboarding process and run periodic reviews on existing partners.
The FDA granted small dispensers a time-limited exemption from certain requirements that runs until November 27, 2026. Know whether you qualify and plan for full compliance before that date arrives.
Master data mismatches between partners, EPCIS schema or version drift, stale credentials that break connections and exception workflows that nobody has tested under time pressure. Most failures cluster around the partner handshake, not within a single organization’s systems.
DSCSA requires interoperable, electronic data exchange aligned with FDA-recognized standards. EPCIS-based approaches are the most common implementation path and the closest thing to an industry standard. You could technically use another approach, but your trading partners will almost certainly expect EPCIS.
Treat it as a documentation and retrieval problem. Assign evidence owners, define systems of record, build an evidence index and run timed retrieval drills. Focus on proving your program works rather than producing legal opinions about compliance status.
FDA’s DSCSA-related resources support activities like wholesale distributor and 3PL reporting. Your team should understand how to use these resources for counterparty validation and for meeting any applicable reporting expectations tied to your ATP status.
Failed partner connections, exception overload and slow evidence retrieval cause the most DSCSA disruption. The fix usually comes down to having the right platform paired with an operating model that matches how your team actually works.
Systech focuses on the outcomes that keep programs running: faster partner onboarding with credential validation built into the process, exception handling governed by defined SLAs rather than email threads, verification workflows with complete request/response logging and evidence retrieval you can execute within 48 hours without pulling people off other work.
UniTrace serves as the operational layer for teams managing DSCSA compliance across trading partners, and it fits into broader regulatory compliance programs for organizations aligning U.S. and global requirements.
If your program has gaps, you want to stress-test what you’ve built, or want to find a product that works best for you, a conversation is a good place to start.
Systech. All rights reserved.
EN 
PT 
FR 
DE 
